It is well known that patients' with inflammatory arthritis (IA) have an increased risk for cardiovascular (CV) morbidity and mortality based on both the inflammatory process and the increased prevalence of some of the known risk factors for development of CV disease. In 2010 ten evidence based EULAR recommendations for CV management in patients with rheumatoid arthritis (RA) and other forms of IA was published (1). CV risk assessment in all patients with RA was recommended and should be considered for patients with other forms of IA based on national guidelines. This lecture will provide an overview of how we set out to implement these recommendations at a Danish hospital in patients with RA and other forms of IA. The patients' pharmacological treatment and risk factors were assessed together with the patient in planned nurse-led consultations. The patients' 10-year mortality risk was calculated based on the European SCORE system (2). For patients with RA the risk score was adapted by a factor 1.5 if the patient met two of three defined criteria: 1) disease duration of more than 10 years, 2) rheuma-factor positivity and or anti-cyclic citrullinated peptide positivity and: 3) presence of certain extra-articular manifestations. The lecture will provide information about the specific content and delivery of the nurse-led assessments, how they were documented in the national database, Danbio and how the patients identified risk was managed subsequently. Opportunities for future development and research will be discussed.
Peters, M.J., et al., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis, 2010; 69(2): p. 325-31.
Conroy, R.M., et al., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 2003; 24(11): p. 987-1003.
Disclosure of Interest None declared